Physician profile
Christopher E Adams
NPI 1336301563
$1,484.28
in general payments reported to CMS, 2019-2025
26 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $50.68 · 2021: $70.62 · 2022: $209 · 2023: $190 · 2024: $213 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.23 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $216.24 | 2023-2025 | Jelmyto |
| Intuitive Surgical, INC. | $198.12 | 2019-2022 | |
| Janssen Biotech, INC. | $197.15 | 2019-2023 | Erleada |
| Biosense Webster, INC. | $91.40 | 2025 | Carto 3 |
| Coloplast Corp | $88.24 | 2021-2025 | |
| Boston Scientific Corporation | $85.71 | 2019-2025 | Axonics, Advance Xp |
| Procept Biorobotics Corporation | $68.07 | 2024 | Aquabeam System |
| Sumitomo Pharma America, INC. | $66.64 | 2025 | Gemtesa, Orgovyx |
| Astrazeneca Pharmaceuticals LP | $58.89 | 2022-2025 | Imfinzi |
| Abbvie INC. | $54.82 | 2019-2020 | |
| Axonics, INC. | $53.06 | 2023-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $39.04 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $33.67 | 2019 | |
| Merck Sharp & Dohme LLC | $28.87 | 2019-2021 | |
| 180 Medical, INC. | $24.39 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $19.69 | 2025 | Barrigel |
| Myovant Sciences INC. | $19.44 | 2021 | |
| Rochester Medical Corporation | $18.53 | 2021 | |
| Dendreon Pharmaceuticals LLC | $17.88 | 2025 | Provenge |
| Cook Medical LLC | $17.72 | 2024 | Resonance |
| Progenics Pharmaceuticals, INC. | $16.23 | 2022 | |
| Laborie Medical Technologies Corp. | $16.04 | 2024 | Endosheath Technology |
| Endo Pharmaceuticals INC. | $14.81 | 2022 | |
| Integra Lifesciences Corporation | $14.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.38 | 2019 | |
| Urovant Sciences INC | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.